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Original Article
A Combination of NT-4/5 and GDNF Is
Favorable for Cultured Human Nigral
Neural Progenitor Cells
Stefano Di Santo1, Morten Meyer2,3, Ange´lique D. Ducray1,4,
Lukas Andereggen1, and Hans R. Widmer1
Abstract
Idiopathic Parkinson’s disease (PD) is a progressive neurodegenerative disorder, clinically manifested by cardinal motor
symptoms including tremor at rest, bradykinesia, and muscle rigidity. Transplantation of dopaminergic (DAergic) neurons is an
experimental therapy for PD, however, it is limited by suboptimal integration and low survival of grafts. Pretreatment of donor
tissue may offer a strategy to improve properties of transplanted DAergic neurons and thereby clinical outcome. We have
previously shown that a combination of neurotrophin-4/5 (NT-4/5) and glial cell line-derived neurotrophic factor (GDNF)
demonstrated additive effects on rat ventral mesencephalic (VM) tissue. The present study investigated the effects of NT-4/5
and GDNF as single factors, or in combination on DAergic neurons, in organotypic explant cultures of fetal human ventral
mesencephalon. For that purpose, free-floating roller-tube cultures were prepared from VM and the equally sized pieces
grown for 1 week in the presence or absence of neurotrophic factors. Both neurotrophic factors increased dopamine content
in the culture medium and in the number of tyrosine hydroxylase immunoreactive neurons, most prominently after combined
GDNF þ NT-4/5 treatment. Culture volumes did not differ between groups while content of lactate dehydrogenase in the
culture medium was moderately reduced in all treated groups. In conclusion, we identified that a combination of GDNF and
NT-4/5 robustly promoted differentiation and survival of human fetal VM DAergic neurons, an observation with potential
promising impact for cell replacement approaches in PD.
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Introduction
Progressive loss of dopaminergic (DAergic) neurons in the
substantia nigra pars compacta is critically implicated for the
motor symptoms observed in patients suffering from Parkin-
son’s disease (PD). While drug therapies provide an effec-
tive means to substitute for the missing intrastriatal
dopamine, long-term treatment often goes together with
severe side effects. In this context, cell replacement strate-
gies in PD have emerged as an experimental therapeutic
concept. Thereby, the transplanted cells serve as a biological
pump releasing dopamine. Human fetal nigral tissue can be
transplanted safely, and it has been shown that grafts sur-
vived and reinnervated the host striatum of PD patients1–4.
This approach, however, is limited by suboptimal survival
and differentiation of grafted DAergic neurons1.
Hence, alternative sources of transplantable DAergic neu-
rons have been investigated including induced pluripotent
stem cells (iPSC) and embryonic stem cells (ESC), but also
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their capacity to reinnervate the diseased striatum in rodents
was found to be critical5. A number of neurotrophic factors
have been described to increase the survival and growth of
DAergic neurons including the glial cell line–derived neuro-
trophic factor (GDNF) and neurotrophin-4/5 (NT-4/5)6.GDNF
belongs to the transforming growth factor-b (TGF- b) super-
family and mediates cellular responses by a multicomponent
receptor complex composed of the rearranged during transfec-
tion (RET) proto-oncogene and GDNF family receptor a. In
cultures of fetalmidbrain,GDNFpromotes survival and differ-
entiation of DAergic neurons and increases high-affinity
dopamine uptake7,8. NT-4/5 is a member of the NT family.
Upon tropomyosin receptor kinase B (TrkB) receptor binding
NT-4/5 initiates intracellular signaling cascades including the
Rat sarcoma-phosphatidylinositol 3-kinase -Protein Kinase
B (Ras-PI3K-Akt) and the phospholipase C-gamma 1 path-
ways9,10. In mesencephalic primary cultures, NT-4/5 has been
shown to enhance the morphological complexity and to stimu-
late the survival of DAergic neurons11,12. In line with these
reports, we have shown that GDNF and NT-4/5 administration
resulted in a significantly higher survival rate of rat ventral
mesencephalic (VM) tyrosine hydroxylase immunoreactive
(TH-ir) neurons grown for 1 week as free-floating roller-tube
(FFRT) cultures and also increased their 3,4-dihydroxyphe-
nethylamine (dopamine; DA) release6.
Transient storage of donor tissue in FFRT culture offers
the possibility of exposing cells with growth factors prior to
grafting. We, and others, have previously shown that pre-
treated donor tissue resulted in a better outcome13. Support
for growth factor pretreatment prior to transplantation is
furthermore given by a recent study which demonstrated that
fibroblast growth factor 2–mediated pregrafting expansion of
primary VM precursor cells considerably improved DAergic
cell survival and functional restoration in a rat model of PD14.
To the best of our knowledge, so far no studies have been
performed analyzing the effects of a combined GDNF and
NT-4/5 administration on VM tissue of human origin.
Hence, in the present study, we aimed at investigating
whether treatment with combined exposure to GDNF and
NT-4/5 improves DAergic neuron survival and augments
dopamine release as compared to a single-factor treatment.
Materials and Methods
Human Tissue
All experiments were carried out in accordance with the
Ethics Committee of the Medical Faculty of the University
of Bern and the Ethics Committee of the State Bern, Switzer-
land (study no. 181/07). Written consent was given by the
women seeking abortion.
Tissue culture. FFRT cultures were prepared from VM derived
from aborted human fetuses as described in detail by Spenger
and colleagues15,16. The embryonic age of the specimen was
8- to 9-wks postconception for analysis of cell numbers and
dopaminecontent and7- to10-wkspostconception forWestern
blot analysis and lactate dehydrogenase (LDH) measurements
as determined by themethod ofEvtouchenko and colleagues17.
In brief, the VM tissue was dissected out and divided into two
equally sized portions corresponding to the left and right side
and then further divided into equally sized small pieces. Each
piece was transferred into labeled conical plastic tubes (BD
Falcon, Allschwil, Switzerland) containing 1 mL of culture
medium and placed in a roller drum in an incubator for
1 wk16. The cultures were grown in medium containing 55%
Dulbecco’s modified Eagle medium (DMEM) (Gibco, Rein-
ach, Switzerland), 32.5% Hank’s balanced salt solution
(HBSS, Gibco), 1.5% glucose, 10% fetal calf serum (Gibco),
and 1% 0.01 M Hepes (Merck KGaA, Darmstadt, Germany).
During the entire culture period, antibiotics (Gibco) were pres-
ent. The culture tubes were randomly assigned to the GDNF
(10 ng/mL; Promega AG, Du¨bendorf, Switzerland), NT-4/5
(10 ng/mL; Promega), the GDNF plus NT-4/5 group, and to
the control group (n¼ 4–12 cultures per group for each of the 3
independent experiments). The medium was changed every
other day. Neurotrophic factors were added at day 0 and then
at each medium change. Control cultures were grown in
medium with no trophic factors added.
Analysis of dopamine content in the culture medium by high-
performance liquid chromatography (HPLC). At the end of the
culture period, the medium was collected and a dopamine-
stabilizing solution (0.22 mg metabisulfite per 50 ml in 7.5%
orthophosphoric acid) was added. Dopamine was deter-
mined using reversed phase HPLC with electrochemical
detection as described in detail elsewhere6. Mean dopamine
content in control cultures was 24.1+ 4.4 pg/mL (mean+
standard error of the mean [SEM]).
Immunohistochemistry and morphometric analyses. Cultures
were washed 2 times with ice-cold HBSS, pooled, and fixed
in 4% paraformaldehyde in 0.1 M phosphate-buffered saline
(PBS; pH 7.4) for 45 min at room temperature followed by
cryoprotection in 20% sucrose in 0.1 M PBS containing
0.01% NaN3 for 24 hours. Cultures were sectioned at 20
mm on a freezing microtome (Frigocut 2800N, Reichert-Jung)
and mounted on gelatin chrome alum–precoated glass slides
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). Sec-
tions were washed in PBS preincubated for 60 min in PBS
containing 0.3% Triton X-100 and 10% horse serum and
incubated for 48 h at 4 C with primary antibodies against
rabbit anti-TH (1:1,000, Pel-Freez Biologicals, Rogers, AR,
USA) diluted in PBS containing 0.1% Triton X-100 and 2.5%
horse serum. After washing, sections were incubated with
biotinylated anti-rabbit antibodies (1:200; Vector, Burlin-
game, CA, USA). Bound antibodies were visualized with the
avidin–peroxidase complex method and the metal enhanced
3,30-diaminobenzidine-based kit (Pierce, Rockford, IL, USA).
Slides were then washed, dehydrated, and covered with Eukitt
(O. Kindler GmbH, Freiburg, Germany). Quantification of
TH-ir neurons was performed by bright-field microscopy by
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means of a neuron tracing system using a 20 objective6. Cell
numbers were corrected for double counting according to
Abercrombie’s formula18 and were normalized as TH-ir cell
densities (number of TH-ir cells/mm2) and shown as percent-
age of controls. Mean TH-ir cell densities in control cultures
were 71.3+ 8.3 cells/mm2 (mean+ SEM). Culture volumes
were assessed by computer-assisted image analysis as
described elsewhere6. Mean culture volumes in control cul-
tures were 0.47+ 0.07 mm3 (mean+ SEM).
Analysis of LDH content in the culture medium. At the end of the
culture period, the medium was collected and used for LDH-
level measurements as described in detail earlier6. Values
are expressed as percentage of controls of 4 independent
experiments (n ¼ 17–20 per group).
Western blotting. Proteins were analyzed by SDS-PAGE mini-
gel electrophoresis as described previously6. Briefly, cultures
were washed 2 times with ice-cold HBSS and then pooled for
each group. The prepared lysates were subjected to a 12%
SDS-PAGE separating gel, and the proteins blotted to a poly-
vinylidene difluoride membrane (Bio-Rad, Basel, Switzerland).
After electrophoretic transfer, the blots were decorated with
mouse anti-TH (1:500; Millipore, Billerica, MA, USA) or
mouse anti-GFAP (1:500; Millipore) antibodies. Visualization
of bound antibody was performed using anti-mouse antibody–
peroxidase conjugates (1:10,000; Nordic Immunological
Laboratories, Tilburg, The Netherlands) and the enhanced
chemiluminescence method (Amersham, Glattbrugg, Switzer-
land). For loading control and densitometric analyses, mem-
branes were reprobed with mouse monoclonal a–tubulin
(1:20,000; Sigma-Aldrich Chemie GmbH, Buchs, Switzer-
land). Experiments were done in triplicate.
Statistics. For the statistical analysis, a commercially available
software package was used (GraphPad Prism 6, La Jolla, CA,
USA). The experimental groups were compared using the
Kruskal–Wallis nonparametric analysis of variance test in
combination with the Dunn’s multiple comparison post hoc
analysis. Differences were considered statistically significant
at P < 0.05. Values are presented as mean+ SEM.
Results
Immunohistochemical analysis of the cultures disclosed higher
TH-ir neuron cell densities in the GDNF, NT-4/5, and GDNF
plus NT-4/5 treated groups (3-fold, 5-fold, and 9-fold after
GDNF, NT-4/5, and the combination treatment, respectively)
as compared to untreated controls (Fig. 1A). Moreover, the
combination treatment resulted in increased survivingTH-ir cell
numbers as compared to all other groups (Fig. 1A). In contrast,
culture volume did not differ significantly between control and
experimental groups with slightly increased volumes found for
the GDNF plus NT-4/5 group (by 22%) as compared to control
groups (Fig. 1B). Similar to theoutcome seenoncell densities of
TH-ir neurons, significantly augmented TH protein levels in
tissue lysate were observed in the growth factor treated groups
as compared to control groups (Fig. 2A and B). We next rea-
soned whether the release of dopamine might have paralleled
these effects on the TH-ir neurons. Indeed, the levels of dopa-
mine in the culture mediumwere increased in all neurotrophic
factor–treated groups (4.5-fold, 5.5-fold, and 6.5-fold after
GDNF, NT-4/5, and the combination treatment, respectively)
as compared to control groups.Accordingly, the treatmentwith
NT-4/5 and GDNF þ NT-4/5 exerted the same increase in
dopamine release in the culture medium (Fig. 1C).
Fig. 1. Effects of glial cell line–derived neurotrophic factor (GDNF;
gray bars), neurotrophin-4/5 (NT-4/5; dark gray bars), and com-
bined neurotrophic factor treatment (black bars) on tyrosine
hydroxylase (TH) positive cell densities (A), culture volume (B),
and dopamine content in the culture medium (C). Ventral mesen-
cephalic (VM) free-floating roller-tube (FFRT) cultures were grown
for 1 wk in absence (control, open bars) or presence of neuro-
trophic factors. Data in the bar graphs are given as a percentage of
control values and are expressed as mean þ standard error of the
mean. *P < 0.05 versus corresponding control. aP < 0.05 versus all
groups.
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Western blot analysis for GFAP did not show increased
levels in the neurotrophic factor–treated cultures as com-
pared to controls (Fig. 2C and D). The level of LDH,
released into the culture medium from dead or degenerating
cells, was lower after growth factor treatment compared to
untreated control cultures (100.0%+ 5.2%, 90.5%+ 1.3%,
91.4%+ 0.9%, and 90.2%+ 1.6% for control, GDNF, NT-
4/5, and the combination treatment, respectively).
Discussion
In the present work, we demonstrate that the combination of
NT-4/5 and GDNF has an additive effect on TH-ir cell num-
bers in organotypic explant cultures of fetal human ventral
mesencephalon. Moreover, we have found that the combined
treatment is superior to each of the single factors in
improving the survival and the expression of structural and
biochemical functional markers of cultured fetal DAergic
neurons. Overall, these observations substantiate and extend
our earlier report on VM-FFRT cultures of rat origin6.
Optimal growth, differentiation, and survival of DAergic
neurons during development require a concerted action of
different neurotrophic factors. In translational settings, sev-
eral studies have addressed whether the neuronal supporting
actions of different neurotrophic factors including GDNF
and neurturin can be exploited to improve the efficacy of
cell transplantation approaches for PD. Indeed, GDNF has
already been reported to reduce apoptosis in DAergic neu-
rons19 and to promote DAergic fiber growth in fetal nigral
grafts20. Application of NT-4/5 and GDNF furthermore pro-
tected DAergic neurons from toxin-induced cell death21, and
GDNF was found to exert antiapoptotic effects on the
Fig. 2. Representative microphotographs tyrosine hydroxylase (TH)-immunoreactive cells from human ventral mesencephalic (VM) free-
floating roller-tube (FFRT) cultures grown for 7 d without (control; A) or with addition of neurotrophin (NT)-4/5 and glial cell line–derived
neurotrophic factor (GDNF; comb; B). Scale bars: 100 mm and 50 mm (inserts). Representative Western blot analyses for TH (C) and glial
fibrillary acidic protein (D) protein levels from human VM free-floating roller-tube FFRT cultures grown for 7 d without (control) or with
addition of NT-4/5 and GDNF (comb). Note that the combined treatment resulted in a significantly increased TH signal intensity as
compared to the control group (C), whereas no difference in GFAP signal intensities between groups was observed (D). Membranes were
reprobed with a-tubulin as a loading control. *P < 0.05 versus corresponding control.
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DAergic neurons19,22. These observations suggest that the
reduction in apoptosis events might be one of the mechan-
isms involved in the higher number of TH-ir neurons in the
NT-4/5- and GDNF-treated samples. Indeed, this notion
seems to be supported by the lower LDH levels measured
after growth factor treatment. Notably and conversely to the
additive actions observed on TH-ir cell densities, however,
levels of released LDH did not differ among the growth
factor-treated groups. Thus, this outcome does not support
the idea that the higher TH-ir cell densities are the result of a
substantial reduction in cell death; rather, these findings
might be better explained by an enhanced specific matura-
tion and/or differentiation of the TH-ir cells subpopulation.
In agreement with this hypothesis, we have observed no
significant differences in culture volume between groups.
Moreover, in agreement with our previous study using cul-
tures of rat origin6, GFAP protein levels were not affected by
the treatments. Nevertheless, the mechanisms underlying the
increased TH-ir cell densities were not investigated in the
present study, and we cannot exclude that other neuronal
phenotypes were also promoted by the treatments. In fact,
it has been reported that GDNF and NTs stimulate the sur-
vival and growth of a wider range of neurons including
striatal and cortical GABAergic neurons9,23–25.
From a functional standpoint in the cell transplantation
paradigm for PD, the capacity to release substantial amounts
of dopamine is a crucial disease-changing pattern. We pre-
viously demonstrated that BDNF treatment increased the
number of cultured DAergic neurons and elevated dopamine
levels in the culture medium26. Moreover, we reported a
moderate but beneficial survival-promoting effect of com-
bined GDNF and BDNF treatment on rat fetal nigral tissue20.
In the present study, HPLC measurements of dopamine in
the culture medium disclosed pronounced effects after single
factor treatment as compared to controls. Interestingly, only
a tendency for additivity was detected. Although this out-
come appears in contrast to the findings of Studer and col-
leagues, that is, that TH-ir cell numbers correlate with
dopamine content in the culture medium27, it should be
noted that in the mentioned study only cultures not exposed
to growth factors were investigated. The mechanisms
accounting for our observation need to be further explored
and might involve differences in the degree of DAergic neu-
ron maturation induced by NT-4/5 and GDNF possibly due
to differences in the expression of the respective receptors.
Importantly to note, even though Mendez et al. reported a
substantial increased fluorodopa uptake in 2 parkinsonian
patients receiving grafts exposed to GDNF,28 it is clearly
necessary to verify the effectiveness of the combined
NT-4/5 and GDNF pretreatment regimen of human mesen-
cephalic tissue in animal models of PD.
Conclusions
Recent evidence supports the view that the intrastriatal deliv-
ery of DAergic neurons might develop into a safe and
effective therapeutic option for PD29. Although the human
iPSC-derived DAergic cells hold a considerable potential
due to the unrestricted availability, high purity, and minor
ethical concerns, they appear to be less effective compared
to the fetal-derived neurons. On the other hand, the limited
availability of fetal donor tissue and the generally poor sur-
vival of the grafted DAergic neurons are still major issues to
be solved for successful cell replacement interventions29.
The present study demonstrates that exposure of human
DAergic nigral neurons grown as FFRT cultures to a com-
bination of GDNF and NT-4/5 significantly improved qual-
ity of donor tissue and that this combination is overall
superior compared to the single-factor treatments. Further
studies in PD will be needed to verify the significance of the
preengraftment treatment described here. Nevertheless, it
can be assumed that our findings likely also have impact for
cell replacement approaches using iPSC- and/or ESC-
derived donor cells.
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